On Friday 14 July 2017, Lilly celebrated 50 years of pioneering research and development at its site in Erl Wood, Surrey (UK). The Lilly Research Centre was established in 1967 and has played a key role in some of the company’s most important scientific breakthroughs, including the discovery of olanzapine (Zyprexa®) for the treatment of schizophrenia and bipolar disorders. Launched in 1996, olanzapine became Lilly’s most successful medicine and has been used to treat millions of patients worldwide. Over 600 people, representing 45 nationalities and 30 different functional disciplines, continue to collaborate from Erl Wood on the discovery and development of new medicines to meet areas of major unmet medical need.
The day of celebration saw leading figures from the world of Alzheimer’s research, neuroscience and medicines development come together to hear about the latest advances in the fight against Alzheimer’s and reflect on the history of the Erl Wood site. Take a look at our interviews from the day below with key figures in the field; Sue Forda (Lilly), Mike Hutton (Lilly), Dan Skovronsky (Lilly), David Reynolds (Alzheimer’s Research UK) and Ginny Acha (ABPI).
This content has been financially supported by Lilly.